P. Todd Korthuis, M.D., M.P.H.
P. Todd Korthuis, M.D., M.P.H.
Associate Professor of Medicine
Program Director, Addiction Medicine Fellowship
Division of General Internal Medicine and Geriatrics
Department of Public Health/Preventive Medicine
Education and Training
B.S., Azusa Pacific University, 1986
M.D., University of Health Sciences/Chicago Medical School , 1987 - 1991
Internship, Naval Medical Center San Diego, 1991-1992
Residency, Yale University School of Medicine, 1996-1998
Chief Residency, Yale University School of Medicine, 1998-1999
Fellowship, West Los Angeles Veterans Administration Ambulatory Care, 2000-2002
M.P.H., University of California Los Angeles, 2000-2002
Dr. Korthuis is a practicing general internist, addictionmedicine provider, and clinician scientist. He began his clinical career treatingpatients living with HIV and became board-certified in addiction medicine in2010. His research focuses on improving integration of addiction treatment indiverse health care settings, including HIV clinics. He serves as PrincipalInvestigator for two international trials funded by the National Institute onDrug Abuse: The CTN-0055/0067 CHOICES trial of clinic-based extended-releasenaltrexone in North American HIV clinics, and the BRAVO trial of clinic-basedbuprenorphine for opioid use disorder in Vietnam HIV clinics. He isco-investigator in the National Institute of Drug Abuse Clinical Trials NetworkWestern States Node, collaborating in clinical trials of opioid,methamphetamine, and cocaine treatment. Honors include the 2008 Lawrence S. Linn Award for research thatimproves the lives of people living with HIV and a 2012-2013 FulbrightScholar award to study integration of HIV and addiction care in Vietnam. Dr.Korthuis serves as Program Director for the OHSU Addiction Medicine Fellowshipand Co-Director of the Oregon Addiction Education and Prevention Initiativethat provides training and support for rural primary care providers inpharmacotherapy for substance use disorders.
American Board of Internal Medicine, 1998-current
American Board of Addiction Medicine, 2010-current
Dr. Korthuis' research focuses on strategies to improve the quality of HIV care and prevention through increasing integration of addiction treatment and HIV services. Dr. Korthuis has served as site principal investigator for the Buprenorphine and HIV Care Evaluation and Support Initiative (BHIVES), a NIDA K23 Career Development Award to study quality outcomes for HIV-infected substance users, the HIV Research Network, and the Enhancing Communication and HIV Outcomes (ECHO) studies. He currently serves as co-investigator for the Western States Node of the NIDA Clinical Trials Network where he serves a site PI for several studies. He was the 2008 recipient of the Lawrence S. Linn Research Award for research that improves the lives of people living with HIV.
Recent Research Projects
PI: Todd Korthuis, MD, MPH
MARC Pilot Project (Methamphetamine Abuse Research Center)
Title: Risky Decision Making in Methamphetamine Users:
The Role of Opioid Blockade The primary goal of this MARC pilot proposal is to probe the neural mechanism of the effect of endogenous opioid blockade on impulsive choice in HIV-infected methamphetamine (MA) users. The proposal extends the scope of a recently funded NIDA award (R21DA033182) assessing neural mechanisms of endogenous opioid blockade on impulsive choice in non-HIV-infected MA users, to include HIV-infected subjects.
- Korthuis PT, Anaya HD, Bozzette SA, Brinkerhoff CV, Mancewicz M, Wang M, Asch SM. Quality of HIV Care within the Veterans Affairs Health System: a comparison using Outcomes from the HIV Cost and Services Utilization Study (HCSUS). Journal of Clinical Outcomes Management, 2004;11(12):765-774.
- Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analysis. Lancet 2006; 368:1503-15.
- Korthuis PT, Josephs JS, Fleishman JA, Hellinger J, Himelhoch S, Chander G, Morse EB, Gebo KA. Substance abuse treatment in HIV: The role of patient-provider discussions. J Substance Abuse Treat 2008; 35(3):294-303. PMC2574740
- Korthuis PT, Zephyrin LC, Fleishman JA, Saha S, Josephs JS, McGrath MM, Hellinger J, Gebo KA. Health Related Quality of Life in HIV-Infected Patients: The role of substance use. AIDS Patient Care and STDs 2008; 22(11):859-67. PMC2596984
- Korthuis PT, Saha S, Fleishman JA, McGrath MM, Josephs JS, Moore RD, Gebo KA, Hellinger J, Beach MC. Impact of Patient Race on Patient Experiences of Access and Communication in HIV Care. J Gen Intern Med 2008; 23(12):2046-52. PMC2596522
- Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care. Journal of Addiction Medicine 2010;4(4):204-210. PMC3002395
- Korthuis PT, Saha S, Chander G, McCarty D, Moore RD, Cohn JA, Sharp VL, Beach MC. Substance Use and the Quality of Patient-Provider Communication in HIV Clinics. AIDS and Behavior 2011;15:832-841. PMC3077450
- Altice FL, Bruce RD, Lucas GM, Lum P, Korthuis PT, Flanigan T, Cunningham C, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch M, Finkelstein R, BHIVES Collaborative. HIV Treatment Outcomes among HIV-infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment and HIV Care: Results from a Multi-site Study. J Acquir Immune Defic Syndr. 2011;56:S22-32. PMC3263431
- Schackman BS, Leff J, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R, BHIVES Collaborative. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S76-82. PMC3270565
- Korthuis PT, Berkenblit GV, Sullivan LE, Cofrancesco J, Cook RL, Bass M, Bashook PG, Edison M, Asch SM, Sosman JM. General Internists' Beliefs, Behaviors, and Perceived Barriers to Routine HIV Screening in Primary Care. AIDS Education and Prevention 2011; 23(3) Suppl:53-66. PMC3196638
- Korthuis PT, Fiellin DA, Rongwei F, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flannigan T, Boverman J, McCarty D, BHIVES Collaborative. Improving Adherence to HIV Quality of Care Indicators in Persons with Opioid Dependence: The Role of Buprenorphine. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S83-90. PMC3066190
- Agwu AL, Jang SS, Korthuis PT, Araneta MRG, Gebo KA. Pregnancy Incidence and Outcomes in Vertically and Behaviorally HIV-Infected Youth. JAMA 2011;305(5):468-70. PMC3252765
- Saha S, Sanders DS, Korthuis PT, Cohn JA, Sharp VL, Haidet P, Moore RD, Beach MC. The role of cultural distance between patient and provider in explaining racial/ethnic disparities in HIV care. Patient Educ Couns 2011; 85(3):e278-e284.
- Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, Altice FL, BHIVES Collaborative. Improved quality of life for opoid dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S39-45. PMC3073082
- Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D, Metsch LR. Injection Behaviors among Injection Drug Users in Treatment: the Role of Hepatitis C Awareness. Addictive Behaviors 2012; 37(4): 552-555. PMC3288438.
- HIV Medicine
- Addiction Medicine
- General Internal Medicine
Patient Care Locations
Dr. Korthuis continues to teach residents and students in the OHSU HIV clinic and conducts HIV-related and addiction medicine-related trainings for students, residents, and fellows. He serves as faculty for the Northwest AIDS Education and Training Center (AETC) and the Northwest Frontier Addiction Technology Transfer Center (ATTC) , conducting trainings for community providers throughout the Pacific Northwest.
Dr. Korthuis is a translational health services researcher conducting studies to improve the quality of care and address substance abuse issues for persons living with HIV infection.